^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Marginal Zone Lymphoma |
| Drug: | amulirafusp alfa (IMM0306) (CD20 inhibitor, CD47 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary results from a phase I/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.
Published date:
05/25/2023
Excerpt:
...we report the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy results of the dose escalation stage in a phase I/II study in patients (pts) with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma….IMM0306 was well-tolerated and with a robust preliminary anti-tumor activity especially in pts with R/R FL and MZL.
DOI:
10.1200/JCO.2023.41.16_suppl.7527
